[1]Louis Wing Cheong Chow,Wings Tjing Yung Loo,Qing Liu. Individualized therapy for breast cancer:a decade of improvement[J].中华乳腺病杂志：电子版,2015,9(4):223-230.
　[J].Chinese Journal of Breast Disease (Electronic Version),2015,9(4):223-230.
点击复制

 Individualized therapy for breast cancer:a decade of improvement()

中华乳腺病杂志：电子版[ISSN:1674-0807/CN:11-9146/R]

卷:
第9卷
期数:
2015年4期
页码:
223-230
栏目:
专家论坛
出版日期:
2015-08-01

文章信息/Info

作者:
 Louis Wing Cheong Chow1; 2;  Wings Tjing Yung Loo2;  Qing Liu2
 1 Institute for Applied Research in Medicine and Health, Macao University of Science and Technology, Macao, China; 2 Organisation for Oncology and Translational Research and UNIMED Medical Institute, Hong Kong,China
关键词:
 ; Breast neoplasms; Drug therapy; Individualized therapy
文献标志码:
A
摘要:
 Breast cancer is the most prevalent female cancer in both the developed and less developed world. According to WHO 2013 estimates, there were over 522 000 female breast cancer deaths in 2012[1]. Breast cancer (1.7 million) was the second commonly diagnosed cancer worldwide after lung cancer (1.8 million), and followed by colorectal cancer (1.4 million) [1]. In less developed regions, breast cancer is the highest cause of cancer death in women; in more developed regions, it is the second highest cause of cancer death, after lung cancer.
Breast cancer incidence is on the rise worldwide. In Asia, the highest incidence is in the Philippines, followed by Singapore, China (including Hong Kong) and other highly populated countries such as Japan, Thailand and India[2-3]. The differences in breast cancer incidence and mortality are highly evident between the east and the west. The mortality of breast cancer is decreasing in western cohorts, but it is increasing in Asian cohorts [4]. Breast cancer often occurs at younger ages in Asian patients, unlike their Western counterparts(peak age:45-50 years vs 65 years)[4-5]. Lower mortality in western countries may be attributed to the well-established breast cancer screening and preventative programs.

相似文献/References:

[1]Per,Eystein,Lnning.Role of molecular markers in breast cancer therapy[J].中华乳腺病杂志：电子版,2010,4(5):479.
[2]Louis,Wing-Cheong,Chow,等.Potential of a COX2 inhibitor in lowering chemotherapyinduced neutropenia[J].中华乳腺病杂志：电子版,2010,4(5):496.
[3]Kentaro,Tamaki,Hironobu,等.An analysis of vascularity and neovascularization in surgical pathology materials of breast carcinoma and its clinical significance[J].中华乳腺病杂志：电子版,2010,4(5):521.
[4]Jun-Xiang,Zhang,Da-Qiang,等.P21-activated kinase 1 and breast cancer[J].中华乳腺病杂志：电子版,2010,4(5):544.
[5]Adrian,YS,Yip,等.Methods of early detection: would clinical breast examination and breast ultrasonography be a good alternative to mammography?[J].中华乳腺病杂志：电子版,2011,5(6):646.
[6]Kentaro,Tamaki,Hironobu,等.New development of breast cancer histological evaluation related to determination of therapeutic option for the patients[J].中华乳腺病杂志：电子版,2011,5(6):721.
[7]Wings,T.,Y.,等.Application of single and combination therapy of clarithromycin and tamoxifen to suppress breast cancer cell proliferation and metabolism[J].中华乳腺病杂志：电子版,2012,6(1):45.
[8]Satoko,Suzuki,Miki,等.Efficacy of volume navigation in assessment of extent of breast cancer[J].中华乳腺病杂志：电子版,2012,6(5):533.
[9]Chong,Le,等.Is it necessary to do axillary dissection in old women with breast cancer? A meta-analysis of randomized clinical trials[J].中华乳腺病杂志：电子版,2012,6(6):622.
[10]TANG,Qi,等.Giant phyllodes tumor in both breasts:one case report and literature review[J].中华乳腺病杂志：电子版,2013,7(2):142.

更新日期/Last Update: 2016-05-04